According to a 2020 status report on the global burden of cancer worldwide there were 19.3 million new cancer cases and 10 million cancer deaths. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10%), prostate (7.3%) and stomach cancer (5.6%).
It is estimated that 2 out of 3 patients will likely develop dermatological adverse events from the anticancer therapy. Due to the frequency and varied clinical presentation of skin toxicities, their negative impact on the patient quality of life and their impact on oncological treatment outcomes, the field of Oncodermatology has emerged to provide supportive care to cancer patients and survivors.
Tarian Pharma’s ambition is become a leader of Oncodermatology supportive care and provide patients and health care professionals with innovative and effective medicines to prevent skin toxicities.
Among skin toxicities, EGFRi-induced folliculitis, known as acne rash, is mainly affecting face, upper chest and back in patients with colorectal cancer treated with EGFR inhibitors. Depending on the drug/dose used, folliculitis rash is observed in 50-100% of patients.
Rradiotherapy-induced dermatitis (RID) develops almost in all breast cancer patients with 30-40% of women developing moderate and severe forms (i.e., grade 2 or higher).
Alopecia, the partial or complete loss of hair, is a frequent consequence of breast cancer therapy and can be psychologically and socially devastating. Between 60% and 100% of patients with breast cancer experience complete alopecia during chemotherapy.
Hand and Foot Syndrome (HFS), is a progressively developing inflammation of the palms and soles, it can occur with several types of chemo or targeted therapies and can lead to intense pain interfering with daily activities. Depending on the product/doses used, HFS frequency varies between 10-80%.